multiple dose bio­equi­va­lence study [Design Issues]

posted by wienui  – Germany/Oman, 2020-08-10 10:00 (1496 d 12:54 ago) – Posting: # 21847
Views: 2,475

Hi Loky do & Helmut,

❝ If we have solifenacin 6 mg (immediate-release) / tamsulosin 0.4 mg modified-release product combination, is multiple-dose bioequivalence study required to be submitted to the European authorities in addition to fast & fed studies, as there is no specific guidance for this product & in GCC region fast & fed studies only accepted.


Yes, you need an MD (SS) study as Helmut mentioned above. Please note that the GCC GL was adopted originally from the EMA GL, therefore it follows it, although some points could be not clear included.

Cheers,
Osama

Complete thread:

UA Flag
Activity
 Admin contact
23,225 posts in 4,879 threads, 1,652 registered users;
42 visitors (0 registered, 42 guests [including 8 identified bots]).
Forum time: 22:55 CEST (Europe/Vienna)

We absolutely must leave room for doubt
or there is no progress and no learning.
There is no learning without having to pose a question.
And a question requires doubt.
People search for certainty.
But there is no certainty.    Richard Feynman

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5